Trial Profile

A Phase 1/2 Study to Assess the Safety and Efficacy of MultiStem Therapy in Subjects With Acute Respiratory Distress Syndrome

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 27 May 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Invimestrocel (Primary)
Indications Adult respiratory distress syndrome
Focus Adverse reactions; Therapeutic Use
Acronyms MUST-ARDS
Sponsors Athersys; Healios

Most Recent Events

30 Nov 2021 Results presented in an Athersys media release.
30 Nov 2021 According to an Athersys media release, data from this trial has been published in the journal Intensive Care Medicine.
23 Sep 2020 According to an Athersys media release, this study will be evaluated through 28 days for the primary clinical assessment and further assessed through a one-year follow-up period.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com